RCM
ASBP

Radcliffe Capital Management’s Aspire Biopharma ASBP Stock Holding History

Radcliffe Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-85
Closed -$1.11M – 100
2023
Q4 		$1.11M Hold
85
– – 0.15% 105
2023
Q3 		$1.1M Sell
85
-40
-32% -$516K 0.14% 157
2023
Q2 		$1.59M Sell
125
-418
-77% -$5.25M 0.14% 197
2023
Q1 		$6.84M Buy
543
+10
+2% +$125K 0.43% 58
2022
Q4 		$6.59M Buy
533
+283
+113% +$3.47M 0.21% 127
2022
Q3 		$3.04M Hold
250
– – 0.07% 449
2022
Q2 		$2.99M Buy
+250
New +$2.99M 0.07% 485

Other funds holding ASBP

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Radcliffe Capital Management's ASBP Position: Q1 2024 in Review

Radcliffe Capital Management sold out of Aspire Biopharma (ASBP) in Q1 2024, closing a stake of 85 shares — an estimated $1.11M sold.

Radcliffe Capital Management first reported a position in ASBP in Q2 2022 and held it in 7 quarters. The position peaked at $6.84M in Q1 2023. 17 funds tracked by Wall St. Rank hold ASBP as of Q1 2024.

  • Radcliffe Capital Management reported no remaining Aspire Biopharma position as of Q1 2024 after selling out during the quarter.
  • Radcliffe Capital Management sold 85 Aspire Biopharma shares in Q1 2024, an estimated $1.11M.
  • Radcliffe Capital Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 7 quarters.
  • Radcliffe Capital Management's Aspire Biopharma position peaked at $6.84M in Q1 2023.
  • 17 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2024.

Based on Radcliffe Capital Management's 13F filing for Q1 2024, filed 15 May 2024.